Redeye comments on Active Biotech’s proposed fully guaranteed rights issue of SEK70m, which is large...
YIT reports its Q3 results on October 30th. The quarter is expected to be quite slow, with housing u...
Redeye provides an initial take following Q-linea’s Q3 2025 report.
* Q3 sales lower than expected (-5% vs. ABGSCe) * Major untapped potential in Recycling * Long-term ...
Redeye is positive about the acceptance of Paxman’s PLCS system for CIPN into the FDA’s Safer Techno...
* Q3 report due on 23 October * We cut 2025e EBITA by 3% but raise 2026e-2027e by 3-2% * Share is tr...
* Q3 report due 23 October; we cut '25e-'27e EPS by ~2% * We expect further margin and cash flow rec...
Redeye notes an interesting press release from Genovis confirming a SEK11m order from a global pharm...
Stabila utdelningar eller fallande trend? Redeye tittar närmare på bolagets utdelningar.
* Sales -5%, adj. EBIT SEK -2m vs. ABGSCe * Seasonal effects impacted Aesthetics segment * Recycling...
DT reports Q3 results on Oct 30. Q3 will be another weak quarter, while Q4 could be relatively bette...
Redeye considers I-Tech’s Q3 figures relatively soft, missing our top-line estimate by 10% and EBITD...
Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc.
Redeye updates its estimates and valuation after OEM’s Q3 2025 report.
Organic growth could return in Q3 y/y after being negative for the past seven quarters.
